There were no limiting safety or tolerability signals identified with the addition of valganciclovir to pirfenidone therapy in patients with idiopathic pulmonary fibrosis.
Sheila JacobsContributing Writer
Sheila Jacobs is the president of STJ Editorial Services. For more than 25 years, Sheila has been providing writing, fact-checking, and editorial services to numerous clients in the medical education, promotional, and managed care arenas, from the conceptual stage through completion of the final editorial product. Her focus has been in a diverse array of therapeutic areas.